Pomegranate lists hormone products alongside its weight offering, which puts it among the minority here acknowledging that women arrive with more than one thing going on. But a product listing and a clinical programme are different, and this page can only assess what is actually published.
What is published is thin. There is no whole-woman clinical programme, no described dosing protocol and no disclosed pharmacy, which is why this scorecard carries more blanks than almost any other.
Here is how Pomegranate Health reads against each promise of the Whole-Woman Charter. Each promise is marked none, partial or strong; price is shown but is never part of the rating. GLP-1 medications are not a treatment for endometriosis.
Full pricing appears after a $75 consultation, so the $179 figure is what is visible in advance rather than the complete picture. This structure is common enough in telehealth and it is disclosed rather than concealed, but it does mean you pay to see the terms. Treat the consult as a cost of evaluating this option, not as part of your care.
Five of seven rows score zero, with metabolic framing and human help at partial. We want to be precise: that is a statement about published information, not an allegation about the clinicians. The consult may well reveal more than the website does. But every other provider here tells you more before you spend anything, and that comparison is the relevant one.
Put these to Pomegranate Health in writing, and keep the reply.
Pomegranate rates lowest on this Charter, and the reason is information rather than any judgment about the care. Too little is published to assess, and the structure asks you to pay before finding out. Others here answer these questions for nothing.
What is above comes from what this provider chooses to publish, and providers revise their terms without saying so — treat it as a starting point and check it yourself. Havelle is editorial, not clinical: none of this is medical advice, and GLP-1 medications are not a treatment for endometriosis.